唑来膦酸与阿仑膦酸钠治疗骨质疏松患者的疗效比较及对血清 25-(OH)D、BALP、BGP 的影响分析 (Chinese)

Comparison of the efficacy of zoledronic acid and alendronate in the treatment of osteoporosis and their influence on serum 25-(OH) D, BALP and BGP levels. (English)

Objective To compare the effects of zoledronic acid and alendronate sodium on bone mineral density and serum 25 hydroxyvitamin D(25 (OH) D), osteocalcin (BGP) and bone specific alkaline phosphatase (BALP) levels in patients with osteoporosis (OP). Methods 82 osteoporosis patients attending clinics of our hospital were randomly divided to the study group (41 cases) and the control group (41 cases). All patients received Caltrate D and calcitriol capsules as routine treatment, and patients in the study group were treated with zoledronic acid, and patients in the control group were treated with alendronate sodium. The clinical effects of the two groups were evaluated, and in both groups bone mineral density (BMD) and serum markers of bone metabolism including 25 (OH) D, BGP and BALP were measured before and after treatment. Results The total effective rate was 90. 25% in the study group and 80. 48% in the control group (P < 0. 05). After six-month of treatment, in both groups lumbar spine (L2-4) and right femoral neck BMD increased significantly compared with before treatment( P < 0. 05). After 12 months of treatment,the increase in lumbar spine (L2-4) and right femoral neck BMD were significantly greater in the study group than the control group (P < 0. 05). At 12 months, compared with before treatment levels,in both groups the 25(OH) D levels increased (P< 0. 05), and the BGP and BALP levels decreased (P < 0. 05), but the decline in BGP and BALP levels was greater in the study group than in the control group (P < 0. 05). Conclusion Zoledronic acid was more effective in the treatment osteoporosis than alendronate sodium, significantly increased bone mineral density and reduced BALP and BGP levels, suggesting it could be widely used for the treatment of osteoporosis. [ABSTRACT FROM AUTHOR]

目的比较唑来膦酸与阿仑膦酸钠治疗骨质疏松(OP)患者的疗效及对血清25羟维生素D[25-(OH)D]、骨钙素(BGP)、骨特异性碱性磷酸酶(BALP)的影响。方法将我院收治的82例OP患者随机分为观察组41例和对照组41例。在钙尔奇D和骨化三醇胶丸常规治疗的基础上,观察组患者行唑来膦酸治疗,对照组患者行阿仑膦酸钠治疗。评价两组患者的临床治疗效果,于两组患者治疗前后检测骨密度(BMD)及血清相关骨代谢标志物,包括25-(OH)D、BGP、BALP。结果观察组患者临床治疗的总有效率为90.25%,对照组为80.48%,两组比较差异具有统计学意义(P<0.05)。治疗6个月后,两组患者的平均腰椎正位(L2-4)及右股骨颈BMD较治疗前均增大(P<0.05),但治疗12个月后观察组患者腰椎正位(L2-4)及右股骨颈BMD的增大幅度均高于对照组(P<0.05)。治疗12个月后,两组患者的平均25-(OH)D较治疗前均升高(P<0.05),BGP、BALP较治疗前均下降(P<0.05),但观察组患者BGP、BALP两指标的下降幅度要高于对照组(P<0.05)。结论唑来膦酸治疗OP的临床疗效较阿仑膦酸钠显著,能有效下调BALP、BGP水平,提高患者骨密度,值得临床推广应用。 [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Osteoporosis is the property of Chinese Journal of Osteoporosis and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)